Loading clinical trials...
Loading clinical trials...
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Conditions
Interventions
Daprodustat (GSK1278863)
Placebo
+1 more
Locations
168
United States
GSK Investigational Site
Homewood, Alabama, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Downey, California, United States
GSK Investigational Site
Fresno, California, United States
GSK Investigational Site
Lynwood, California, United States
GSK Investigational Site
Northridge, California, United States
Start Date
March 5, 2018
Primary Completion Date
October 7, 2020
Completion Date
October 7, 2020
Last Updated
April 2, 2024
NCT06884280
NCT07082205
NCT06601712
NCT05251493
NCT07340450
NCT05681871
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions